Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

IDEA Collider: Innovation & Asymmetric Learning in Pharma

IDEA Collider: Innovation & Asymmetric Learning in Pharma artwork

IDEA Collider | Pharma Book Club | Brian Christian

Feb 23, 202150 minAudio
ShareXLinkedInFacebookWhatsAppEmail

With so much at stake in the application of AI/ Machine Learning to pharma, biotech and medicine, this wonderful book touches on biases, systems of learning, and the choices we have to make to properly harness the power of what is possible. Email mike at ideapharma.com to enter a lottery to win a copy of the hardcover book, closing date 26th February. From the page at brianchristian.org: A jaw-dropping exploration of everything that goes wrong when we build AI systems and the movement to fix them. Today’s “machine-learning” systems, trained by data, are so effective that we’ve invited them to see and hear for us - and to make decisions on our behalf. But alarm bells are ringing. Recent years have seen an eruption of concern as the field of machine learning advances. When the systems we attempt to teach will not, in the end, do what we want or what we expect, ethical and potentially existential risks emerge. Researchers call this the alignment problem. Systems cull résumés until, years later, we discover that they have inherent gender biases. Algorithms decide bail and parole - and appear to assess Black and White defendants differently. We can no longer assume that our mortgage application, or even our medical tests, will be seen by human eyes. And as autonomous vehicles share our streets, we are increasingly putting our lives in their hands. The mathematical and computational models driving these changes range in complexity from something that can fit on a spreadsheet to a complex system that might credibly be called “artificial intelligence.” They are steadily replacing both human judgment and explicitly programmed software. In best-selling author Brian Christian’s riveting account, we meet the alignment problem’s “first-responders,” and learn their ambitious plan to solve it before our hands are completely off the wheel. In a masterful blend of history and on-the ground reporting, Christian traces the explosive growth in the field of machine learning and surveys its current, sprawling frontier. Readers encounter a discipline finding its legs amid exhilarating and sometimes terrifying progress. Whether they―and we―succeed or fail in solving the alignment problem will be a defining human story. The Alignment Problem offers an unflinching reckoning with humanity’s biases and blind spots, our own unstated assumptions and often contradictory goals. A dazzlingly interdisciplinary work, it takes a hard look not only at our technology but at our culture―and finds a story by turns harrowing and hopeful. Read more at: https://brianchristian.org/the-alignment-problem/

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. ESMO 2026 Preview: Key studies that could fundamentally change the oncology landscape.

    Oct 22, 202642 minAudio

    In this episode of the IDEA Collider podcast, Alex Gray, Chief Medical Officer at SAI & IDEA Pharma, John Barry, Executive Vice President at SAI, and Tom Brockbank, Senior Consultant at IDEA Pharma, look ahead to ESMO...

    Credit the people on this episode

  2. AI-Driven Pharma Market Research: Synthetic Users - with Kwame Ferreira & Rebecca Gould.

    Oct 7, 202641 minAudio

    Welcome back to the IDEA Collider podcast. In this episode, host Rick Ritacco sits down with Kwame Ferreira, Founder of Synthetic Users, and Rebecca Gould, President, Strategic Consulting & Analytics Business Unit at...

    Credit the people on this episode

  3. The Keytruda Blueprint: Alex Gray, David Radwaner, and Tom Brockbank on the IO Revolution: Part II

    Sep 14, 202636 minAudio

    Welcome back to the IDEA Collider podcast. In this second instalment of our future of immuno-oncology series, Alex Gray is joined by colleagues David Radwaner and Tom Brockbank to discuss what lies ahead for cancer...

    Credit the people on this episode

  4. Targeting the Totality of MS: Jason Tardio on Immunic’s Combined Neuroprotective and Anti-Inflammatory Strategy

    Jul 16, 202649 minAudio

    Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Jason Tardio, President and COO of Immunic, to discuss the rapidly evolving landscape of Multiple Sclerosis (MS) treatment. For 30...

    Credit the people on this episode

  5. The Future of Psychedelic Medicine: Clinical Strategy and Scaling Access.

    Jul 1, 202650 minAudio

    Welcome to a special edition of IDEA Collider’s "Deep Medicine" series. In this episode, host Alex Gray sits down with Athina Metaxa, a consultant at IDEA Pharma and psychedelic research expert, to discuss the rapidly...

    Credit the people on this episode